



Follow-up to the preliminary results about use of systemic of O₂/O₃ in the treatment of Novel Coronavirus Pneumonia (COVID-19). Date and Version No:6 - 10/04/2020

Country Region	Protocol	Remarks / Side effects
ISCO3 Theoretical protocol for Intervention in case of Mild /Moderate /Severe COVID-19 + IN CRITICAL STATUS O₂/O₃ are non-considering	MAH Blood vol. 100 → 150 mL. Proportion of O ₂ /O ₃ : Blood 1:1. Daily for 5 days + 3 weekly x 10/14 days. Firs week 30 µg/mL, last 40 µg/mL Or O ₃ SS 5 →3 µg/kg b.w. a day x 10 days or EBOO	Consider glutathione 1,2 g or / and Vitamin C 1-3 g in 100 mL of saline, in case of <i>Compassionate use</i> . Two times a week for 4 weeks
ISCO3 Theoretical protocol for Prevention Medical doctor or occupational risk people	MiAH 5 mL Blood + session 1/2: 5 mL O ₃ 25 µg/mL; session 3/4: 5 mL O ₃ 30 µg/mL; session 5/6: 5 mL O ₃ 30 µg/mL. Once a week. Or Rectal insufflation 3 times a week 40 µg/mL /100 mL	Consider: glutathione 600 mg or / and Vit. C 1 g in 100 mL of saline i.v. once a week. Oral: Once a day: N-acetyl cysteine 600 mg for 30 days, plus Vit.D 2000 UI (o 50 µg). Twice a day Vit. C 500 mg. Melatonin 3/5 mg 30 min before sleep.
SPAIN (Applying ISOC3 protocol) N= 20	ISCO3 suggested Protocol O ₃ SS 5→3 µg/kg b.w. a day x 10 days Vit.C + GSH 1,2 g i.v. in 100 mL Saline	↓ Fever in 3-4 days ↓ Viral Load in 3-4 days S.E.: Jarisch-Herxheimer like reaction? cytokine storm?
Location: Hosp Nuestra Señora del Rosario. Ibiza	MAH ?	?
CHINA Reg. ChiCTR2000030102 Researcher: Huiling Huang. Location: Tianjin Haihe Hospital N patients = 4 FINISHED*	MAH 100 mL blood + 100 mL, up-to 200 mL, 1-2 times a day. Critical case 2-4 times a day. Time schedule: 10 d	Patient feels better Chest tightness is improved ↑ 50 % PaO ₂ after the first application S.E.: Allergy?
Reg. ChiCTR2000030006	Researcher: Han Linlin Location: Union Hospital of Wuhan Tongji University Status: No news	
USA Researcher: P. Brian Volpp Location: Palomar Med. Center. California Status: Protocol approved by IRB	EBOO 7L of blood in 1h, once a week	In star-up
ITALY Condition: Mild /Severe Researcher: Fabio Araimo Location: Hosp. Umberto I. Roma N= 60 Control /60 O ₃ Sponsor: FIO /WFOT Approval: EC Hosp. Umberto I /Univ. Sapienza Roma	MAH Proportion of O ₂ /O ₃ : Blood 1:1. 100 mL O ₂ /O ₃ 30 µg/mL, every 12 h for 14 days. Or RIO ₃ Day 1 100 mL, Day 2 150 mL, Day 3-14 200 mL, O ₂ /O ₃ 30 µg/mL + Vit. C 3g + GSH 600 mg every 12 h, 6 h after MAH.	Fast ↓ RT-PCR 2019-nCoV ↓ IL6
Researcher: Alessio Zambello Marcello Salvaggio Location: Brescia N= 10 Critical Sponsor FIO / FINALIZED	MAH 2 mL/kg b.w. O ₂ /O ₃ 50 µg/mL, 2 times a day. Day 1 and Day 3, GSH i.v. 1,2 g	S.E.: 1 case of arrhythmia, atrial fibrillation with elevated ventricular response. Not associated with treatment. NO CLINICAL IMPROVEMENT
Researcher: Amado del Monte / Carlo Tascini Location: Hosp. Univ. Santa M. Misericordia / Udine Approval: Pending EC Univ. Friuli N= 36 treated / total 200	MAH 200 mL. O ₂ /O ₃ XX µg/mL, 4/5 times	Clinical improvement in 35 /36 patients.
Researcher: Mariano Franzini Location: 17 Hosp.? N= 11 Sponsor SIOOT Approval: ?	Mild: MAH blood: 150-200 mL 1:1 O ₃ 30/ 40 µg/mL. 2 times a week. Ozonized oil spray 2 times a day. Moderate: MAH blood: 150-200 mL 1:1 O ₃ 40/ 50 µg/mL. 3 times a week. Ozonized oil spray 2/3 times a day. Ozonized water 250 mL 3 times a day. Severe / Critical: ?	Improvement in terms of: PaO ₂ , clinical symptoms, Renal function, Cardiac frequency, ↓ Fever, ↓PCR, removal of assistant respiration in 5 days. S.E.: 1 death not associated with treatment septic shock
Researcher: Eugenio Caradonna Location: Univ. Sacro Cuore Roma / Campo Basso. Status: Submitted to Etic Committee Sponsor AIRO /SIMCRI	ISCO3 Protocol	Pending for etic committee approval.
IRAN Dr. Izadi / Dr. Effat N. Shirazi	MAH	In star-up

Legend: E.C., etic committee; S.E. side effects; IRB, Institutional Review Boards; FIO; New Italian Federation of Ozone Therapy; O3SS, ozonized Saline Solution; MAH, Mayor autohemotherapy; EBOO, Extracorporeal blood oxygenation-ozonation; SIOOT, Società Scientifica Ossigeno Ozono Terapia; AIRO, Accademia Internazionale di Ricerca in Ossigeno-Ozono Terapia.

* No more patients available, author will write a case report; ? Not confirmation available.